Helvacı N - Search Results

1

Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Dinçer BT, Usta AM, Kural A, Helvacı N, Uçar A, Urgancı N. Dinçer BT, et al. Among authors: helvaci n. BMC Pediatr. 2024 Dec 23;24(1):834. doi: 10.1186/s12887-024-05327-4. BMC Pediatr. 2024. PMID: 39716084 Free PMC article.

2

Is it possible to identify COVID-19 infection-related biomarkers during pregnancy?: A prospective study in Turkish population.

Özer Aslan İ, Doğan K, Kural A, Baghaki S, Helvaci N, Ekin M, Yaşar L. Özer Aslan İ, et al. Among authors: helvaci n. Medicine (Baltimore). 2024 May 10;103(19):e38062. doi: 10.1097/MD.0000000000038062. Medicine (Baltimore). 2024. PMID: 38728492 Free PMC article.

3

Does COVID-19 reduce anti-Mullerian hormone levels in women of reproductive age in late periods of infection?

Doğan K, Kural A, Özer Aslan İ, Erdoğan A, Gönül M, Dura MC, Helvacı N, Ekin M. Doğan K, et al. Among authors: helvaci n. J Turk Ger Gynecol Assoc. 2024 Dec 10;25(4):231-237. doi: 10.4274/jtgga.galenos.2023.2023-2-3. J Turk Ger Gynecol Assoc. 2024. PMID: 39658890 Free PMC article.

4

Investigating the blood rheology in the first trimester pregnancies with high risk for preeclampsia.

Uygur L, Kabasakal Ilter M, Helvacı N, Mokresh ME, Kahya M, Muvaffak E, Elmuhammed MH, Ayhan I, Kumru P. Uygur L, et al. Among authors: helvaci n. Clin Hemorheol Microcirc. 2024;86(4):519-530. doi: 10.3233/CH-232026. Clin Hemorheol Microcirc. 2024. PMID: 38143340

5

The study of sirtuins in breast cancer patients before and after radiotherapy.

Helvacı N, Saraçoğlu H, Yıldız OG, Kılıç E. Helvacı N, et al. Turk J Med Sci. 2021 Jun 28;51(3):1354-1359. doi: 10.3906/sag-2012-195. Turk J Med Sci. 2021. PMID: 33705642 Free PMC article.

6

Polycystic ovary syndrome as a metabolic disease.

Helvaci N, Yildiz BO. Helvaci N, et al. Nat Rev Endocrinol. 2024 Nov 28. doi: 10.1038/s41574-024-01057-w. Online ahead of print. Nat Rev Endocrinol. 2024. PMID: 39609634 Review.

7

Current and emerging drug treatment strategies for polycystic ovary syndrome.

Helvaci N, Yildiz BO. Helvaci N, et al. Expert Opin Pharmacother. 2023 Jan;24(1):105-120. doi: 10.1080/14656566.2022.2108702. Epub 2022 Aug 7. Expert Opin Pharmacother. 2023. PMID: 35912829 Review.

8

The impact of ageing and menopause in women with polycystic ovary syndrome.

Helvaci N, Yildiz BO. Helvaci N, et al. Clin Endocrinol (Oxf). 2022 Sep;97(3):371-382. doi: 10.1111/cen.14558. Epub 2021 Jul 19. Clin Endocrinol (Oxf). 2022. PMID: 34288042 Review.

9

Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis.

Helvaci N, Eyupoglu ND, Karabulut E, Yildiz BO. Helvaci N, et al. Front Endocrinol (Lausanne). 2021 Feb 25;12:598249. doi: 10.3389/fendo.2021.598249. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33716962 Free PMC article.

10

Klotho gene G395A and C1818T polymorphisms in acromegaly: Association with clinical presentation and comorbidities.

Helvaci N, Kabacam S, Dagdelen S, Lay I, Karabulut E, Mut M, Alikasifoglu M, Erbas T. Helvaci N, et al. Clin Endocrinol (Oxf). 2021 Apr;94(4):598-605. doi: 10.1111/cen.14380. Epub 2020 Dec 9. Clin Endocrinol (Oxf). 2021. PMID: 33296101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters